October 18, 2024

Stronger together: miniature robots in convoy for endoscopic surgery

Stronger together: miniature robots in convoy for endoscopic surgery

Miniature robots on the millimeter scale often lack the strength to transport instruments for endoscopic microsurgery through the body. Scientists at the German Cancer Research Center (DKFZ) are now combining several millimeter-sized TrainBots into one unit and equipping them with improved “feet”. For the first time, the DKFZ team was able to perform an electric surgical procedure on a bile duct obstruction experimentally with a robotic convoy.

© dkfz.de

The list of conceivable applications for miniature robots in medicine is long: from targeted drug application to sensing tasks and surgical procedures. An arsenal of robots has already been developed and tested for this range of tasks, from the nanometer to the centimeter scale.

However, the little helpers available today reach their limits in many tasks. For example, in endoscopic microsurgery. The required instruments are often too heavy for a single millimeter-sized robot to carry to its destination. Another common problem is that the robots often have to move by crawling. However, the surfaces of numerous body structures are covered with mucus on which the robots slip and cannot move.

“Spikes” on the feet provide three times the propulsive force
A team led by Tian Qiu at the DKFZ in Dresden has now developed a solution for both of these problems: their TrainBot connects several individual robots on the millimeter scale. The units are equipped with improved anti-slip feet. Together, they are able to transport an endoscopic instrument. The TrainBot unit works wireless; an rotating magnetic field simultaneously controls the individual units. The magnetic control enables movements in a plane with the control of rotation. The external actuation and control system is designed for the distances at the human body scale.

Microsurgery in the bile duct
The Dresden-based DKFZ researchers have already used their robot convoy of three TrainBot units to simulate a surgical procedure. In the case of bile duct cancer, the bile duct often becomes blocked, causing bile to back up, which is a very dangerous situation for those affected. In this case, the occlusion must be opened after an endoscopic diagnosis. To do this, a flexible endoscope is inserted through the mouth into the small intestine and from there into the bile duct. One of the major difficulties here is for the endoscope to navigate around the sharp angle from the small intestine into the bile duct.

“This is where the flexible robot convoy can show its strengths,” says the project leader Tian Qiu. His team demonstrated it using organs removed from a pig. The robot convoy was able to maneuver an endoscopic instrument for electrical tissue ablation in the bile duct. Once the tip of the wire electrode arrives at the site, electrical voltage is applied and a tissue blockage is gradually removed electrically, a procedure known as “electrocauterization”. The wire electrode used was 25 cm long and three and a half times as heavy as a TrainBot unit. “Afterwards, for example, another TrainBot convoy can bring a catheter for fluidic drainage or drug delivery,” says Moonkwang Jeong, the first author of the paper, “After the promising results with the TrainBots in the organ model, we are optimistic that we will be able to develop teams of miniature robots for further tasks in endoscopic surgery.”

Moonkwang Jeong, Xiangzhou Tan, Felix Fischer, Tian Qiu: A Convoy of Magnetic Millirobots Transports Endoscopic Instruments for Minimally-Invasive Surgery
Advanced Science 2024, https://doi.org/10.1002/advs.202308382 

Original News

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp